The newly awarded patent covers the methods and compositions of formulating nanoemulsion vaccines, a unique coupling of oil, water, and antimicrobial surfactant together with antigens from specific pathogens.
Studies in animals demonstrate these vaccines easily penetrate the mucous membrane, where dendritic cells rapidly engulf the antigen and present it to the immune system. This rapid awakening of the immune system via the intranasal route negates the need for inflammatory stimulants used in traditional vaccines, which can cause pain and swelling at the site of vaccination, said Dr. Baker.
"We present antigen in an optimal location where it can most directly access the immune system," added Baker. "As a result, there is no need to prime the immune system with immunostimulants in order to provoke its recognition of the antigens."
Moreover, the vaccine requires no harsh chemicals to attenuate the
whole virus and render it harmless, because the nanoemulsion itself kills
the antigen. Advantages of the nanoemulsion vaccines include:
-- nasal delivery, the entry point of most respiratory infections
-- development of rapid mucosal immunity followed by systemic immunity
-- antigen-sparing capability
-- thermally stable, requires no refrigeration
-- needle-free, easy to administer
The development of the nanoemulsion platform began in 1998 and is supported, in part, by a $6.3 million grant from the Bill and Melinda Gates Foundation to the Michigan Nanotechnology Institute for Medicine and Biological Sciences, which is led by Dr. Baker. The new patent for nanoemulsion vaccines (#7,314,624 B2) is licensed to NanoBio Corporation on an exclusive, worldwide basis. With this new patent, NanoBio now holds five U.S. patents and has filed numerous additional applications in various jurisdictions.
NanoBio(R) Corporation is a privat
|SOURCE NanoBio Corporation|
Copyright©2008 PR Newswire.
All rights reserved